Module 1: Clinical Application of BTCE's

Only available as part of a package

Introduction
Taking a "Bite: out of Multiple Myeloma
Taking a "Bite" Out of Lymphoma
Taking a "Bite" Out of Small Cell Lung Cancer

After completing this activity, the participant should be better able to:

• Discuss mechanisms of action and therapeutic roles of US Food and Drug Administration (FDA)-approved bispecific T-cell engagers (BTCEs) in hematology/oncology malignancies.

• Evaluate clinical trial data and guideline recommendations for BTCEs in multiple myeloma, lymphoma, and small cell lung cancer.

• Apply patient-specific factors to individualize treatment plans for patients receiving BTCE therapy.

• Compare BTCEs to other immunotherapeutic approaches, such as chimeric antigen receptor T-cell therapy, in terms of efficacy, safety, and logistics.

C. Brooke Adams, PharmD, BCOP

Orlando Health Cancer Institute

C. Brooke Adams is a board-certified Clinical Pharmacy Specialist in Malignant Hematology, Stem Cell Transplantation, and Cellular Therapy and the PGY-2 Oncology Residency Program Coordinator at the Orlando Health Cancer Institute. She completed her Doctorate of Pharmacy with research concentration at East Tennessee State University and her PGY-1 pharmacy practice and PGY-2 oncology residencies at Indiana University Health. She is a preceptor for UF and LECOM pharmacy students, PGY-1 and PGY-2 residents and is extensively involved in the education of hematology/oncology fellows and advanced practice providers. She is an active member of HOPA, FLASCO, NCODA, the OPN-FL Chapter, and ASTCT. She recently received the New Practitioner Award from HOPA in 2023 and is a member of the 2022 class of 40 under 40 in cancer presented by AVBCC.

C. Brooke Adams, PharmD, BCOP, has the following financial relationships to disclose, Pfizer, Genmab/AbbVie, Incyte, BMS, Advisory board: Genmab/AbbVie, Amgen, GSK, Johnson & Johnson, Consultant: BMS, Johnson & Johnson.

Emilie Aschenbrenner, PharmD, BCOP

Medical College of Wisconsin

Emilie Aschenbrenner is a board-certified Clinical Pharmacist in Stem Cell Transplantation and Cellular Therapy and the Hematology Clinical Coordinator at Froedtert and the Medical College of Wisconsin. She completed her Doctorate of Pharmacy at the University of Wisconsin, Madison and her PGY-1 pharmacy practice residency at Froedtert Hospital. She is a preceptor for PGY-1 and PGY-2 residents. She is an active member of HOPA, NCODA, Pharmacy Society of Wisconsin, and ASTCT and recently served on the CTN Pharmacy Research Committee. In addition, she has authored review articles, presented research posters, and given presentations both regionally and nationally.

Emilie Aschenbrenner, PharmD, BCOP, has the following financial relationships to disclose, BMS, Astellas, Incyte, Genmab/AbbVie, Sanofi, BeiOne, Amgen, Advisory board: Amgen, Regeneron, Syndax

Megan May, PharmD, BCOP, FHOPA, FAPO

Baptist Health Lexington’s Cancer Center

Megan May is a Clinical Oncology Pharmacy Specialist at Baptist Health Lexington’s Cancer Center in Lexington, Kentucky. She received her Doctor of Pharmacy from Samford University’s McWhorter School of Pharmacy in Birmingham, Alabama, and completed a Pharmacy Practice Residency at Shands Jacksonville Medical Center and a Hematology/Oncology Pharmacy Residency at the Medical University of South Carolina. She is a Board-Certified Oncology Pharmacist. In addition to direct patient care, Dr. May plays an active role in the education of pharmacy students and residents. She has been involved at the national level with a number of professional organizations on various committees and positions over the years. In addition, she has authored review articles, presented research posters, and given presentations both regionally and nationally.

Megan May, PharmD, BCOP, FHOPA, FAPO, has the following financial relationships to disclose, Amgen, AstraZeneca, Advisory board: Amgen, Consultant: Amgen